← Klinické štúdie • Transplantácia obličky
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
Targeting the B Cell Response to Treat Antibody-Mediated Rejection With Carfilzomib and Belatacept (CarBel)
Stručný súhrn
The purpose of this study is to evaluate the safety and efficacy of carfilzomib and belatacept, administered with steroids and maintenance immunosuppression, in kidney transplant recipients with donor-specific antibody (DSA)-associated graft injury. Participants will be followed for 52 weeks after starting investigational therapy, including protocol biopsies at 3 months and 12 months after start of investigational therapy. The study will also assess changes in immune cell responses, blood and urine biomarkers, and biopsy-based pathomic features associated with antibody-mediated graft injury.
Základné údaje
| Ochorenia | Kidney Transplant Rejection |
|---|---|
| Intervencie |
BIOLOGICAL: Carfilzomib BIOLOGICAL: Belatacept |
| Sponzor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Plánovaný počet | 25 |
| Začiatok | 2026-05-29 |
| Predp. ukončenie (primárne) | 2027-06-30 |
| Krajiny | United States |
| Posledná aktualizácia | 2026-05-26 |